Abstract
Background: Inflammatory markers are crucial in diagnosing and monitoring rheumatoid arthritis. Patients with rheumatoid arthritis (RA) live with constant pain that limits their daily activities. Our study highlights the effects of disease activity on the quality of life in patients with rheumatoid arthritis.
Methods: Swollen joint count (SJC), tender joint count (TJC), and visual activity scale (VAS) were utilized to acquire patients' subjective feelings of wellness and their performance of routine daily activities to determine the disease activity. The patient's erythrocyte sedimentation rate (ESR) was measured at the clinical hematology laboratory using the Westergren method. The Quality of Life was rated on a scale of 1 to 10.
Results: Our study found that disease activity is inversely proportional to the quality of life. Out of 111 patients, 3 (2.7%) were in remission, 1 (0.9%) had mild disease, 51 (45.9%) had moderate disease, and 56 (50.5%) had high disease activity. The ESR was normal (<20) in 11 patients (9.9%), moderately elevated (20-50) in 56 (50.5%) patients, and very high (>50) in 44 (39.6%) patients. The study revealed that 66% of patients in remission had normal, while 33% had moderately elevated ESR. 12.5% of patients with moderate disease activity had normal ESR, and none with high disease activity had normal ESR. Of 44 patients with high ESR, 7 had moderate disease activity, and 37 had high disease activity. In our study, 60% of patients had a less than 50% quality of life compared to patients with pre-arthritis.
Conclusion: High disease activity affects the productivity and quality of life in patients with rheumatoid arthritis. Assessing the impact of different interventions on the QOL should be an essential task that can help define a holistic and integrative treatment and rehabilitation model for RA patients.
Keywords: Rheumatoid arthritis, disease activity score, erythrocyte sedimentation rate, quality of life, integrative treatment, rehabilitation.
[http://dx.doi.org/10.1016/S0140-6736(01)06075-5] [PMID: 11567728]
[http://dx.doi.org/10.1016/0002-9343(83)90471-0] [PMID: 6660237]
[http://dx.doi.org/10.1186/ar4469] [PMID: 24485007]
[http://dx.doi.org/10.1002/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R] [PMID: 9751089]
[http://dx.doi.org/10.1023/B:QURE.0000018486.91360.00] [PMID: 15085902]
[http://dx.doi.org/10.1016/j.rbr.2014.03.025] [PMID: 25627223]
[http://dx.doi.org/10.1007/s10067-012-2037-x] [PMID: 22903698]
[http://dx.doi.org/10.3109/s10165-007-0604-9] [PMID: 17694261]
[http://dx.doi.org/10.1136/ard.2010.130310] [PMID: 20699242]
[http://dx.doi.org/10.1016/S0140-6736(05)67337-0] [PMID: 16360794]
[http://dx.doi.org/10.1016/S0140-6736(87)90472-7]
[http://dx.doi.org/10.1136/ard.43.1.8] [PMID: 6696524]
[http://dx.doi.org/10.1136/ard.47.8.648] [PMID: 3137902]
[PMID: 15053454]
[PMID: 2254883]
[PMID: 9818651]
[http://dx.doi.org/10.1093/rheumatology/32.suppl_3.9] [PMID: 8508266]
[http://dx.doi.org/10.1093/rheumatology/39.9.1009] [PMID: 10986307]
[http://dx.doi.org/10.1136/ard.60.10.924] [PMID: 11557647]
[http://dx.doi.org/10.1007/s00296-007-0357-y] [PMID: 17505829]
[http://dx.doi.org/10.1136/ard.59.3.223] [PMID: 10700432]
[http://dx.doi.org/10.1136/bmj.1.6055.195] [PMID: 832072]
[http://dx.doi.org/10.1002/art.1780380107] [PMID: 7818570]
[PMID: 9002004]
[http://dx.doi.org/10.1136/ard.2007.084459] [PMID: 18490431]
[http://dx.doi.org/10.1186/1477-7525-7-25] [PMID: 19296831]
[PMID: 3418643]
[PMID: 11925083]
[http://dx.doi.org/10.1002/1529-0131(199804)41:4<725::AID-ART21>3.0.CO;2-Z] [PMID: 9550483]
[http://dx.doi.org/10.1007/s11926-009-0053-x] [PMID: 19772833]
[http://dx.doi.org/10.1002/1529-0131(200108)44:8<1736::AID-ART308>3.0.CO;2-I] [PMID: 11508423]
[http://dx.doi.org/10.1136/ard.2003.019992] [PMID: 15458956]